Peer-reviewed veterinary case report
Chemotherapy response and survival in cats with extranodal lymphoma
By Taylor, S S et al.·Published in The Journal of small animal practice·2009·Department of Clinical Veterinary Science, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Feline extranodal lymphoma: response to chemotherapy and survival in 110 cats.
- Species:
- cat
Plain-English summary
A group of 110 cats diagnosed with extranodal lymphoma, which can affect various organs like the nose and kidneys, received different chemotherapy treatments to see how well they responded. Most cats (85.5%) showed a positive response to treatment, with those receiving a specific chemotherapy combination (cyclophosphamide, vincristine, and prednisolone) achieving complete remission in about 72.7% of cases. Cats with nasal lymphoma had the best survival rates, living an average of 749 days after treatment, while those with central nervous system lymphoma had the shortest survival at just 70 days. However, cats that had received corticosteroids before chemotherapy had shorter survival times even if they went into remission.
People also search for: cat lymphoma treatment · feline chemotherapy response · nasal lymphoma survival in cats · corticosteroids effect on cat cancer survival
Abstract
OBJECTIVE: To determine response to treatment, survival and prognostic factors for feline extranodal lymphoma in the UK. METHODS: Records of cats diagnosed with lymphoma of extranodal sites at seven referral centres were reviewed and information on signalment, tumour location, prior treatment and chemotherapy protocol recorded. Factors influencing response to treatment and survival were assessed. RESULTS: One hundred and forty-nine cases met inclusion criteria. Sixty-nine cats had nasal lymphoma, 35 renal, 15 central nervous system, 11 laryngeal and 19 miscellaneous locations. Sixty-six cats received cyclophosphamide, vincristine, prednisolone, 25 Wisconsin-Madison doxorubicin-containing multi-agent protocol, 10 prednisolone alone and nine other combinations. The response rate for the 110 treated cats was 85.5 per cent. Of cyclophosphamide, vincristine, prednisolone treated cats 72.7 per cent achieved complete remission, median survival 239 days. Sixty-four per cent of Wisconsin-Madison treated cats achieved complete remission, median survival 563 days. Cats with nasal lymphoma achieving complete remission had the longest survival (749 days) and cats with central nervous system lymphoma the shortest (70 days). If complete remission was achieved, prior treatment with corticosteroids significantly reduced survival time. CLINICAL SIGNIFICANCE: Cats with extranodal lymphoma respond to chemotherapy and achieve survival times comparable to other locations. Corticosteroid pretreatment reduced survival time in cats achieving complete remission.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19891724/